FMP
Enter
API Tools
Extras
Protagenic Therapeutics, Inc.
PTIX
NASDAQ
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
0.3 USD
0.0412 (13.73%)
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-30.78M
-25.78M
-22.22M
-17.7M
Net Income
-5.53M
-5M
-3.6M
-4.99M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-36.3M
-30.78M
-25.78M
-22.22M
Other Distributions
-5.53M
-5M
-3.56M
-4.52M
All figures are in USD.
